Fig. 7.

Type 1 diabetes subgroups exhibit different responses to CTLA4-Ig treatment. (a) Heatmaps illustrating expression levels of the 916 significantly regulated transcripts belonging to the three modules significantly correlated with 2 h C-peptide AUC at baseline and the placebo-treated arm of TN-09; an annotated heatmap is shown below. The four major subgroups (as shown in Fig. 6d) are indicated for each arm. Well-annotated transcripts are illustrated, and the module to which they belong is indicated by the colour bar on the left. Colour bars are provided that indicate: fold change; baseline C-peptide AUC; rate of C-peptide decline over 24 months; selected CTLA4-Ig responders (as in Fig. 5; blue); selected placebos (as in Fig. 5; ‘Selected fast placebos’; peach); age at baseline; and I.I.₃₅₉. (b) TN-09 participants belonging to subgroups 1–4 exhibit different responses to CTLA4-Ig treatment. Tabulated are subgroup mean values for each metric. Statistical differences were assessed with a two-tailed unpaired Student’s t test, superscript letters denote p < 0.05 for: ^aCTLA4-Ig subgroup 1 vs CTLA4-Ig subgroup 2; ^bCTLA4-Ig subgroup 1 vs CTLA4-Ig subgroup 3; ^cCTLA4-Ig subgroup 1 vs CTLA4-Ig subgroup 4; ^dCTLA4-Ig subgroup 2 vs CTLA4-Ig subgroup 3; ^eCTLA4-Ig subgroup 2 vs CTLA4-Ig subgroup 4; ^fCTLA4-Ig subgroup 3 vs placebo subgroup 3; ^gplacebo subgroup 2 vs placebo subgroup 3; and ^hplacebo subgroup 2 vs placebo subgroup 4